Critical Care | 2021
Find the real responders and improve the outcome of awake prone positioning
Abstract
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Dear editor, We read with great interest of the report by Rosen and colleagues [1] about the effect of awake prone positioning (APP) on intubation rate among patients with moderate to severe hypoxemic respiratory failure (HRF) due to COVID-19. They identified a implemented protocol for APP increased duration of prone positioning, but did not reduce the rate of intubation compared to standard care. From our point of view, some details about whether APP could decrease intubation in patients with HRF due to COVID-19 need to be further clarified. First, in Rosen’s study [1], the patient in standard care group also received a median prone duration of 3.4 h compared with 9.0 h per day in the prone group, which means that the real intervention factor they investigated was whether a prolonged APP could further decrease intubation rate. Therefore, it may be more appropriate to draw a conclusion that prolonged APP did not reduce the rate of intubation in patients with HRF due to COVID-19. Second, Rosen and colleagues [1] reported a 33% intubation rate in both groups, which is much lower than that reported in two other studies [2, 3] with similar baseline characteristics, degree of respiratory failure but shorter APP duration (41% and 49% in the control group and 40% and 58% in the prone group) compared with their investigation. Based on this data, could we speculate that prolonged APP does decrease the intubation rate? Third, in Rosen’s study [1], most patients were put on APP when they were supported with noninvasive ventilation, which is a higher level support than high flow nasal canula (HFNC) [4]. This may indicate that they use the APP more like a “rescue” therapy rather than an “adjunctive” therapy in a late stage of ARF, which may get less response to APP and therefore less difference in intubation rate. In summary, combining this lack of accuracy of comparison of APP and non-APP patients, and the possibly late initiation of APP in the moderate to severe ARF COVID-19 patients, a priori chance of finding a difference in intubation was low and may explain the negative findings for the APP. And further analysis with data from comparison of non-APP populations and prolonged APP group, especially in patients support with HFNC and prolonged APP, is needed for a more settled conclusion. Open Access